• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Improvement of skeletal fragility by teriparatide in adult osteoporosis patients: a novel mechanostat-based hypothesis for bone quality.

作者信息

Sugiyama Toshihiro, Torio Tetsuya, Sato Tsuyoshi, Matsumoto Masahito, Kim Yoon Taek, Oda Hiromi

机构信息

Department of Orthopaedic Surgery, Saitama Medical University , Saitama , Japan.

Department of Oral and Maxillofacial Surgery, Saitama Medical University , Saitama , Japan.

出版信息

Front Endocrinol (Lausanne). 2015 Jan 30;6:6. doi: 10.3389/fendo.2015.00006. eCollection 2015.

DOI:10.3389/fendo.2015.00006
PMID:25688232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4311704/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e784/4311704/adb367e7075b/fendo-06-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e784/4311704/adb367e7075b/fendo-06-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e784/4311704/adb367e7075b/fendo-06-00006-g001.jpg

相似文献

1
Improvement of skeletal fragility by teriparatide in adult osteoporosis patients: a novel mechanostat-based hypothesis for bone quality.特立帕肽对成年骨质疏松症患者骨骼脆性的改善：一种基于新型机械ostat的骨质量假说
Front Endocrinol (Lausanne). 2015 Jan 30;6:6. doi: 10.3389/fendo.2015.00006. eCollection 2015.
2
[Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].甲状旁腺激素（特立帕肽）对骨质疏松症骨质量的影响
Clin Calcium. 2012 Mar;22(3):343-55.
3
[Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].甲状旁腺激素（特立帕肽）对骨质疏松症骨量和骨质量的影响
Nihon Rinsho. 2011 Jul;69(7):1264-9.
4
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.特立帕肽[重组人甲状旁腺激素(1 - 34)]对绝经后骨质疏松症女性皮质骨的影响。
J Bone Miner Res. 2003 Mar;18(3):539-43. doi: 10.1359/jbmr.2003.18.3.539.
5
Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.特立帕肽（生物合成人甲状旁腺激素1-34）：骨质疏松症治疗的新范例。
Basic Clin Pharmacol Toxicol. 2004 Jun;94(6):260-70. doi: 10.1111/j.1742-7843.2004.pto940602.x.
6
Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.评估特立帕肽在接受抗吸收治疗时发生骨折或对先前抗吸收治疗不耐受的骨质疏松症患者中的依从性、接受度和耐受性：一项为期18个月的多中心、开放标签、前瞻性研究。
Clin Ther. 2007 Sep;29(9):2055-67. doi: 10.1016/j.clinthera.2007.09.024.
7
[Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].[重组甲状旁腺激素治疗重度骨质疏松症——病例系列]
Przegl Lek. 2011;68(7):391-5.
8
Bone's mechanostat: a 2003 update.博恩的机械ostat：2003年更新版。 （注：这里“mechanostat”可能是个特定专业术语，不太明确其准确通用译名，可根据具体医学领域进一步准确翻译）
Anat Rec A Discov Mol Cell Evol Biol. 2003 Dec;275(2):1081-101. doi: 10.1002/ar.a.10119.
9
[Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].[用于骨与钙代谢紊乱的治疗药物——特立帕肽，甲状旁腺激素（1-34）每日皮下注射]
Clin Calcium. 2007 Jan;17(1):48-55.
10
Parathyroid hormone (1-84) and teriparatide in the treatment of postmenopausal osteoporosis.甲状旁腺激素（1-84）与特立帕肽治疗绝经后骨质疏松症
Womens Health (Lond). 2006 May;2(3):447-57. doi: 10.2217/17455057.2.3.447.

引用本文的文献

1
Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.重组人甲状旁腺激素（1-34）在治疗绝经后骨质疏松症方面的疗效和安全性与阿仑膦酸钠相似。
Medicine (Baltimore). 2018 Nov;97(47):e13341. doi: 10.1097/MD.0000000000013341.
2
Synthesis and Promotion of the Osteoblast Proliferation Effect of Morroniside Derivatives.莫诺苷衍生物的合成及促成骨细胞增殖作用的研究。
Molecules. 2018 Jun 11;23(6):1412. doi: 10.3390/molecules23061412.
3
Osteoporosis Therapy: Bone Modeling during Growth and Aging.

本文引用的文献

1
An evidence-based perspective on vitamin D and the growing skeleton.关于维生素D与骨骼生长的循证观点。
Osteoporos Int. 2015 Apr;26(4):1447-8. doi: 10.1007/s00198-014-2975-z. Epub 2014 Dec 2.
2
The Contribution of Experimental in vivo Models to Understanding the Mechanisms of Adaptation to Mechanical Loading in Bone.实验体内模型在理解骨骼对机械加载适应机制中的贡献。
Front Endocrinol (Lausanne). 2014 Oct 1;5:154. doi: 10.3389/fendo.2014.00154. eCollection 2014.
3
Short-term bone formation is greatest within high strain regions of the human distal radius: a prospective pilot study.
骨质疏松症治疗：生长与衰老过程中的骨重塑
Front Endocrinol (Lausanne). 2017 Mar 9;8:46. doi: 10.3389/fendo.2017.00046. eCollection 2017.
4
Full 24-month treatment course with daily teriparatide: a mechanistic insight.每日使用特立帕肽进行24个月的完整疗程：一项机制性见解。
Osteoporos Int. 2016 Aug;27(8):2635-6. doi: 10.1007/s00198-016-3630-7. Epub 2016 May 6.
5
Proton pump inhibitors and fracture: they impair bone quality and increase fall risk?质子泵抑制剂与骨折：它们会损害骨质并增加跌倒风险吗？
Osteoporos Int. 2016 Apr;27(4):1675-1676. doi: 10.1007/s00198-016-3509-7. Epub 2016 Feb 9.
6
Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis.罗莫索单抗和布洛索单抗：针对机械应力相关刺激治疗骨质疏松症的替代药物。
Front Endocrinol (Lausanne). 2015 Apr 21;6:54. doi: 10.3389/fendo.2015.00054. eCollection 2015.
短期骨形成在人类桡骨远端的高应变区域最为显著：一项前瞻性初步研究。
J Biomech Eng. 2015 Jan;137(1):0110011-5. doi: 10.1115/1.4028847.
4
Warfarin use and fracture risk: an evidence-based mechanistic insight.华法林的使用与骨折风险：基于证据的机制性见解。
Osteoporos Int. 2015 Mar;26(3):1231-2. doi: 10.1007/s00198-014-2912-1. Epub 2014 Oct 10.
5
Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.骨质疏松症治疗：来自骨骼自然稳态系统的新见解。
Osteoporos Int. 2015 Feb;26(2):443-7. doi: 10.1007/s00198-014-2923-y. Epub 2014 Oct 7.
6
Bone remodelling in humans is load-driven but not lazy.人类的骨骼重塑是由负荷驱动的，而不是懒惰的。
Nat Commun. 2014 Sep 11;5:4855. doi: 10.1038/ncomms5855.
7
Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis.文献综述：特立帕肽治疗对骨质疏松症患者髋部的影响。
Bone. 2014 Oct;67:246-56. doi: 10.1016/j.bone.2014.07.014. Epub 2014 Jul 15.
8
Vitamin D supplementation and fracture risk in adults: a new insight.成人补充维生素D与骨折风险：新见解
Osteoporos Int. 2014 Oct;25(10):2497-8. doi: 10.1007/s00198-014-2798-y. Epub 2014 Jul 3.
9
Changes in the degree of mineralization with osteoporosis and its treatment.骨质疏松症及其治疗过程中矿化程度的变化。
Curr Osteoporos Rep. 2014 Sep;12(3):338-50. doi: 10.1007/s11914-014-0218-z.
10
The contribution of collagen crosslinks to bone strength.胶原蛋白交联对骨强度的作用。
Bonekey Rep. 2012 Sep 19;1:182. doi: 10.1038/bonekey.2012.182.